[ccp4bb] Scientific Coordinator post - grade 8 Oxford University
Please forward If you know anyone who might be interested in a drug discovery senior scientific coordinator post ... We are seeking to appoint a Programme Manager/Scientific Coordinator at the University of Oxford's Centre for Medicines Discovery (CMD). The CMD was established in 2020 with the ambition to help pioneer new treatments for disease (https://www.cmd.ox.ac.uk/). To realise this ambition, the CMD is forming extensive collaborations with academics across the University of Oxford and beyond to help translate basic science into new drug discovery projects, as well as partnerships with industry to develop drug leads into new medicines. This role presents an exciting opportunity to engage with a large number of world-leading academics and clinicians, as well as funders and industry representatives on a diverse portfolio of projects. The postholder will help to establish strategic alliances for the department, help to write funding applications for new projects and contribute to their successful project management. You will be expected to supervise an associated project manager and will have the support of other Senior Programme Managers and Principal Investigators in the department. Successful projects will have a clear research and financial path to the clinic. This position is offered full time on a fixed term contract until 31 March 2026 (with potential for extension) and is funded by NIHR BRC Oxford and Oxford Health. Job link can be found here - Job Details (corehr.com)<https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=170842> Also on linkedin https://www.linkedin.com/jobs/view/3922102066 closing date of 3 June 2024. Thanks Alex Bullock alex.bull...@cmd.ox.ac.uk<mailto:alex.bull...@cmd.ox.ac.uk> To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
[ccp4bb] Postdoc post for E3 ligase structural & Chem Biol - Oxford Univ, UK
My group has a postdoc position available on a large EU IMI-funded grant “EUbOPEN” to generate chemical inhibitors and PROTAC handles for E3 ubiquitin ligases to advance the field of targeted protein degradation by the ubiquitin-proteasome system. Based at the Centre for Medicines Discovery, University of Oxford, postholders will produce recombinant human Cullin-RING E3 ligases and perform biochemical and biophysical assays to assess the binding of small molecule ligands and substrates, including Kd or IC50 determination. You will also conduct crystallisation screens to obtain ligand co-structures for structure-based drug design. The role involves access to state-of-the-art facilities and significant teamwork with academic and industry partners. Full job and application details are here: Job Details (corehr.com)<https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=162042> Prof Alex Bullock Centre for Medicines Discovery Nuffield Dept of Medicine University of Oxford https://www.cmd.ox.ac.uk/team/alex-bullock https://www.cmd.ox.ac.uk/research/growth-factor-signalling-and-ubiquitination To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
[ccp4bb] Postdoc / PhD posts available: University of Oxford (kinase crystallography)
My group has 3 posts in advertising right now on protein kinase crystallography at the Centre for Medicines Discovery, University of Oxford, UK: 155976 -Postdoctoral Scientist - Receptor Kinase Structural Biology Job Details (corehr.com)<https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=155976> 155977- Postdoctoral Scientist - CDK Kinase Structural Biology Job Details (corehr.com)<https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=155977> Funded PhD post (Graduate Scholarship) on ACVR1 kinase/FOP Link here<https://www.findaphd.com/phds/project/structural-biology-of-receptor-kinase-signalling-driving-cancer-and-genetic-disease/?p141576> Informal enquires can be made to alex.bull...@cmd.ox.ac.uk<mailto:alex.bull...@cmd.ox.ac.uk> Thanks Alex. https://www.cmd.ox.ac.uk/team/alex-bullock To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
[ccp4bb] Postdoc position Oxford Univ - Structural and Chemical Biology of E3 Ligases
A postdoc position is available in the group of Alex Bullock, University of Oxford, to study the structural and chemical biology of E3 Ligases as part of the EU-funded "EUbOpen" consortium, with funding until 30 April 2025. The project will support the next generation of PROTACs/molecular glues for targeted protein degradation. Nature Reviews Drug Discovery volume 18, pages 949-963 (2019) https://www.nature.com/articles/s41573-019-0047-y The postholder will optimise purification and crystallisation systems for human Cullin-RING E3 ligase substrate adaptor proteins, solve their structures and study their interactions with substrate proteins, peptides and low molecular weight compounds. The post will involve significant collaborative teamwork internally, as well as with external academic and industry partners. Applications close at noon 10 November 2021. Full details are available here: Job Details (corehr.com)<https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=153890> Informal enquires can be sent to alex.bull...@cmd.ox.ac.uk<mailto:alex.bull...@cmd.ox.ac.uk> https://www.cmd.ox.ac.uk/team/alex-bullock https://www.cmd.ox.ac.uk/research/growth-factor-signalling-and-ubiquitination To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
[ccp4bb] Univ of Oxford 2 postdoc positions available
Two postdoctoral positions are available in the group of Alex Bullock, University of Oxford. The posts will support the EU-funded "EUbOpen" consortium that aims to generate chemical inhibitors for druggable protein families, including ubiquitin ligases (E3s) and solute carriers (SLCs). Both posts will involve significant collaborative teamwork between partners from academia and industry. Enquires can be sent to alex.bull...@cmd.ox.ac.uk<mailto:alex.bull...@cmd.ox.ac.uk> (1) Postdoctoral Scientist, Structural and Chemical Biology of E3 Ligases The postholder will optimise efficient expression, purification and crystallisation systems for novel human E3 ligase proteins and study their interactions with substrate proteins, peptides and low molecular weight compounds. Structures will be determined with the goal to develop highly selective chemical probe molecules. This post is offered full-time on a fixed term contract until 30 April 2025. Applications close at noon 9 August 2021. Full details are available here Job Details (corehr.com)<https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=152015> (2) Postdoctoral Scientist, Chemical Biology Assays The postholder will design and optimise biochemical and cellular assays to screen protein targets of different classes against small molecule compound collections and validate hits with orthogonal biophysical assays. Opportunity also exists for further structural and functional studies. You will work independently and as part of a team to complete research projects and draw conclusions from analysing all available data. This post is offered full-time on a fixed term contract until 30 April 2025. Applications close at noon 4th August 2021. Full details are available here Job Details (corehr.com)<https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=152014> To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
[ccp4bb] Univ of Oxford Job opening for Senior Scientist/Future group leader
We are seeking a highly motivated Senior Scientist with an interest in drug discovery and rare diseases to join the new Centre for Medicines Discovery at the University of Oxford. The successful candidate will initially join the group of Alex Bullock for work on an EU-funded project, "EUbOpen", but will also be encouraged to secure future funding to establish their own independent research group on rare disease drug discovery. The EUbOpen consortium involves partners from academia and industry and will involve significant collaborative teamwork. EUbOpen aims to generate chemical inhibitors for druggable protein families, including ubiquitin ligases (E3s) and solute carriers (SLCs). The project involves multi-disciplinary work spanning structural, chemical and cellular biology and seeks applicants with an outstanding track record in one or more of these areas. This post is offered full-time on a fixed term contract until 30 April 2025. Applications close at noon on 18 August 2021. Full details are available here Job Details (corehr.com)<https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=151308> Enquires can be sent to alex.bull...@cmd.ox.ac.uk<mailto:alex.bull...@cmd.ox.ac.uk> To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
[ccp4bb] Oxford Postdoc position available for E3 ligase structural & chemical biology
My group at the University of Oxford is seeking a postdoc for work on E3 ubiquitin ligases as part of a 5 year EU IMI2 consortium project "EUbOpen", which aims to develop chemical inhibitors and protac handles for novel E3 ubiquitin ligases. The post will involve working with E3 proteins to solve crystal structures, develop biochemical and biophysical assays and screen small molecule compounds. More background to the project can be read in Nature Reviews Drug Discovery (2019) 18, 949-963. Job advert is here: https://www.jobs.ac.uk/job/CCM080/postdoctoral-scientist-structural-and-chemical-biology-of-e3-ligases Alex Bullock Nuffield Department of Medicine University of Oxford https://www.eubopen.org/ https://www.cmd.ox.ac.uk/team/alex-bullock https://www.cmd.ox.ac.uk/news/work-starts-on-international-eubopen-chemogenomics-effort To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
[ccp4bb] Job advert - Principal Investigator - Integral Membrane Proteins, University of Oxford
I hope this will PI job posting might interest some of you... A Principal Investigator post is available at the University of Oxford to lead an existing medium-sized research group participating in the EU IMI2 EUbOpen and ReSOLUTE consortia. The group is focused on the structure determination of human integral membrane proteins, particularly Solute Carrier (SLC) proteins, by X-ray crystallography and/or cryo-EM, as well as the development of binders, including small molecule chemical inhibitors/agonists and antibodies/nanobodies. Applicants should have relevant technical expertise and experience of managing staff. The successful candidate will benefit from a large portfolio of expression constructs, structural projects and assays already developed by the team. The post is funded to 30 April 2025 in the first instance. Host institution: https://www.cmd.ox.ac.uk/team Advert link: https://my.corehr.com/pls/uoxrecruit/erq_jobspec_version_4.display_form?p_company=10_internal_external=E_display_in_irish=N_process_type=_applicant_no=_form_profile_detail=_display_apply_ind=Y_refresh_search=Y_recruitment_id=148147 Kind regards Alex To unsubscribe from the CCP4BB list, click the following link: https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB=1 This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list hosted by www.jiscmail.ac.uk, terms & conditions are available at https://www.jiscmail.ac.uk/policyandsecurity/
[ccp4bb] SGC Oxford Symposium: Exploiting Disease Genomics to Catalyse New Medicines; June 14th
[cid:image001.png@01D3C766.E1037C50] CCP4 colleagues may be interested to attend the SGC Oxford's upcoming symposium "Exploiting Disease Genomics to Catalyse New Medicines" which will take place at St. Catherine's College, Oxford on 14th June 2018. Full details and links for registration are below (£50 academic; £100 industry): https://www.thesgc.org/tep-symposium-2018 The international programme includes talks from leading academics and industry members at ICR, LifeArc, Open Targets, SGC, Eli Lilly, The Brain Tumour Charity and the Universities of Oxford/Cambridge/Cardiff/Dundee/British Columbia and will showcase novel potential targets for translational research, including results from the SGC's Target Enabling Packages (TEPs) programme. A poster session will also be held. For any queries, please contact jonathan.l...@sgc.ox.ac.uk<mailto:jonathan.l...@sgc.ox.ac.uk> Alex Bullock SGC Oxford
[ccp4bb] SGC Oxford Symposium: Exploiting Disease Genomics to Catalyse New Medicines; June 14th
[cid:image001.png@01D3C766.E1037C50] We're pleased to announce that registration is now open for SGC Oxford's upcoming symposium "Exploiting Disease Genomics to Catalyse New Medicines" which will take place at St. Catherine's College, Oxford on 14th June 2018. Full details and links for registration are below (£50 academic; £100 industry): https://www.thesgc.org/tep-symposium-2018 The international programme includes talks from leading academics and industry members at ICR, LifeArc, Open Targets, SGC, Eli Lilly, The Brain Tumour Charity and the Universities of Oxford/Cambridge/Cardiff/Dundee/British Columbia and will showcase novel potential targets for translational research, including results from the SGC's Target Enabling Packages (TEPs) programme. A poster session will also be held. For any queries, please contact jonathan.l...@sgc.ox.ac.uk<mailto:jonathan.l...@sgc.ox.ac.uk> Alex Bullock SGC Oxford
[ccp4bb] PhD position available at SGC, University of Oxford
A scholarship-funded DPhil (PhD) studentship position is available at the SGC, University of Oxford, for the academic year starting October 2017. The closing date for applications will be 12 noon UK time, 6th January 2017. Interviews will take place on 24th & 25th January 2017. Scholarship is available for UK nationals only, but funding options are available for other nationalities. Application and project details are copied below: Characterisation of the drug target ACVR1/ALK2 Supervisors: Dr Alex Bullock, Dr Gillian Farnie Project Overview A multidisciplinary DPhil project is available using structural, cellular and chemical biology approaches to advance our ongoing drug discovery efforts targeting the BMP receptor kinase ALK2, encoded by the gene ACVR1. Gain of function mutations in the intracellular kinase domain of ALK2/ACVR1 cause the childhood brain tumour DIPG (diffuse intrinsic pontine glioma) and the rare bone disease FOP (fibrodysplasia ossificans progressiva) (Nat Genet. 2014; 46, 457-61). There are currently no effective treatments for either condition and prognosis is poor. The ALK2 kinase is a member of the BMP/TGF-beta receptor family that activates both the Smad transcription factor and p38 MAPK signaling pathways by phosphorylation. Ligands of the BMP/TGF-β superfamily (BMPs, Nodal, Activins, GDFs, TGF-βs) are secreted growth factors well known for their roles in determining stem cell fate and tissue repair. While some members such as GDF11 have been controversially famed as the "elixir of youth" (Science 2014; 344, 649-52), many are oppositely linked to human disease. You will elucidate the molecular mechanisms that cause ALK2 deregulation and characterize the actions and potency of small molecule ALK2 inhibitors in development in our group (J Med Chem 2014; 57, 7900-15). Key questions include: how does ALK2 activity drive cancer? How do the disease mutations affect the receptor's structure and function? How are different signalling pathways affected? What protein-protein interactions are changed? Why do oncogenic ALK2/ACVR1 mutations occur together with specific Histone H3 K27M mutations? Do epigenetic inhibitors improve the efficacy of ALK2 inhibitors? Training Opportunities You will learn about protein structure, cellular signalling and drug discovery. Training will be given in all aspects of molecular biology from routine cloning and mutagenesis to protein expression and purification using bacterial and human cells. Wild-type and mutant proteins will be analysed using bioinformatic, cellular, biochemical and biophysical techniques (including mass spectrometry, fluorescence plate readers and calorimetry). As part of the Structural Genomics Consortium (SGC) you will make use of state of art facilities for protein crystallisation, X-ray diffraction and structure determination. The student will also benefit from extensive collaborations with international collaborators, patient groups, clinicians and pharmaceutical companies. A named scholarship is available for this project for candidates with UK nationality and residency. http://www.ndm.ox.ac.uk/for-applicants For informal queries, contact: alex.bull...@sgc.ox.ac.uk References Sinha M, Jang YC, Oh J, Khong D, Wu EY, Manohar R, Miller C, Regalado SG, Loffredo FS, Pancoast JR, Hirshman MF, Lebowitz J, Shadrach JL, Cerletti M, Kim MJ, Serwold T, Goodyear LJ, Rosner B, Lee RT, Wagers AJ. (2014). Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science, 344, pp. 649-52. Chaikuad A, Alfano I, Kerr G, Sanvitale CE, Boergermann JH, Triffitt JT, von Delft F, Knapp S, Knaus P, Bullock AN. (2012). Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva. J. Biol. Chem., 287, pp. 36990-8. Mohedas AH, Wang Y, Sanvitale CE, Canning P, Choi S, Xing X, Bullock AN, Cuny GD, Yu PB. (2014). Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. J. Med. Chem., 57, pp. 7900-15. Chaikuad A, Bullock AN. (2016). Structural Basis of Intracellular TGF-β Signaling: Receptors and Smads. Cold Spring Harb Perspect Biol, [Epub] Taylor KR, Vinci M, Bullock AN, Jones C. (2014). ACVR1 mutations in DIPG: lessons learned from FOP. Cancer Res., 74, pp. 4565-70. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, Castel D, Grasso CS, Vinci M, Carvalho D, Carcaboso AM, de Torres C, Cruz O, Mora J, Entz-Werle N, Ingram WJ, Monje M, Hargrave D, Bullock AN, Puget S, Yip S, Jones C, Grill J. (2014). Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet., 46, pp. 457-61.
[ccp4bb] Kinase postdoc positions available at SGC, Oxford University
Two postdoc positions are available at the SGC labs at the University of Oxford to work on the structure and inhibition of human protein kinases. The first is a Wellcome Trust funded project (CAMSEED) working with Stefan Knapp to develop inhibitors against the protein kinase CaMK1D in breast cancer. The second position with Alex Bullock is to characterise the structure and inhibition of kinases implicated in Huntington's disease. Applicants interested in either position can apply using the posting on jobs.ac.uk linked below (closing date 12 noon on 26 August 2014): http://www.jobs.ac.uk/job/AJK107/postdoctoral-scientist-structural-biology/
